Physician profile
Mridula A Jacob
NPI 1023491701
$4,800.19
in general payments reported to CMS, 2019-2025
21 companies · $3,110 in 2025
The $3,110 reported for 2025 was more than what 77% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $128 · 2021: $16.90 · 2023: $392 · 2024: $1,027 · 2025: $3,110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,369 · Education: $99.99 · Consulting Fee: $61.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,368.96 |
| Education | $99.99 |
| Consulting Fee | $61.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,562.73 | 2020-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $631.48 | 2024-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $545.73 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $343.91 | 2023-2025 | Cuvitru, Hyqvia, Eohilia |
| Amgen INC. | $320.27 | 2019-2025 | Tezspire, Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $306.59 | 2023-2025 | |
| Ars Pharmaceuticals Operations, INC. | $255.02 | 2025 | Neffy |
| Csl Behring | $156.18 | 2023 | Haegarda |
| Regeneron Healthcare Solutions, INC. | $127.94 | 2025 | Dupixent |
| Sanofi-Aventis U.S. LLC | $99.99 | 2024 | |
| Blueprint Medicines Corporation | $74.77 | 2024-2025 | Ayvakit |
| Abbvie INC. | $71.49 | 2024 | |
| Optinose US, INC. | $62.07 | 2025 | |
| Adma Biomanufacturing LLC | $61.08 | 2025 | |
| Ani Pharmaceuticals, INC. | $45.63 | 2025 | Purified Cortrophin Gel |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $28.59 | 2025 | Xolair |
| Biocryst US Sales Co., LLC | $24.51 | 2024 | Orladeyo |
| Pfizer INC. | $21.95 | 2023 | |
| Leo Pharma INC. | $20.77 | 2025 | Anzupgo |
| Pharming Healthcare, INC. | $19.87 | 2023 | Ruconest |
| Greer Laboratories, INC. | $19.62 | 2025 | Oralair |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mridula Jacob listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.